Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(1):4-5; doi:10.1093/jnci/93.1.4
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Fisher, R. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fisher, R. I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 1, 4-5, January 3, 2001
© 2001 Oxford University Press

EDITORIAL

Autologous Bone Marrow Transplantation for Aggressive Non-Hodgkin's Lymphoma: Lessons Learned and Challenges Remaining

Richard I. Fisher

Affiliations of author: Cardinal Bernardin Cancer Center, Loyola University Stritch School of Medicine, Maywood, IL, and Lymphoma Committee, Southwest Oncology Group Operations Office, San Antonio, TX.

Correspondence to: Richard I. Fisher, M.D., Cardinal Bernardin Cancer Center, Loyola University Stritch School of Medicine, Rm. 255, 2160 S. First Ave., Loyola University Medical Center, Maywood, IL 60153.

Long-term follow-up of numerous single-institution and national cooperative group clinical trials have confirmed that at least one third of all patients with advanced-stage, aggressive non-Hodgkin's lymphoma (NHL) are cured by their initial treatment with combination chemotherapy. Results of the National Cancer Institute (Bethesda, MD)-sponsored High Priority Lymphoma Study established CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) as the standard therapy for these patients because it was equally as effective as any of the other popular regimens while being less toxic and less costly (1).

However, more than half of these patients were not . . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
L. E. Abrey, C. H. Moskowitz, W. P. Mason, M. Crump, D. Stewart, P. Forsyth, N. Paleologos, D. D. Correa, N. D. Anderson, D. Caron, et al.
Intensive Methotrexate and Cytarabine Followed by High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Patients With Newly Diagnosed Primary CNS Lymphoma: An Intent-to-Treat Analysis
J. Clin. Oncol., November 15, 2003; 21(22): 4151 - 4156.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. I. Fisher
Autologous Stem-Cell Transplantation as a Component of Initial Treatment for Poor-Risk Patients With Aggressive Non-Hodgkin's Lymphoma: Resolved Issues Versus Remaining Opportunity
J. Clin. Oncol., November 15, 2002; 20(22): 4411 - 4412.
[Full Text] [PDF]